Skip to content

Falsification of medication used in kidney transplants puts patients at risk in several countries

· by Redacción Orgullo Dominicano · 2 min de lectura
falsificación medicamento Simulect

The World Health Organization (WHO) has issued an urgent alert about the falsification of medication used in kidney transplants, detected in at least three countries. It concerns the immunosuppressant Simulect (basiliximab), a crucial drug for preventing acute rejection in adults and children who have received a kidney transplant.

This medication is used to prevent rejection of the transplanted organ, a process that can put the patient’s life at risk if not controlled. The falsification of medication used in kidney transplants represents a significant public health danger, as adulterated or nonexistent products can be ineffective or even harmful.

Impact and detection of the falsification

Counterfeiters use advanced techniques to replicate Simulect’s packaging and presentation, making it difficult for patients and healthcare personnel to identify. WHO has noted that timely detection was possible thanks to pharmaceutical checks at strategic distribution points.

The implications for transplant patients are critical: administering a fake medication can increase the risk of organ rejection, severe medical complications, and potentially loss of the transplant.

Context and background of Simulect use

Simulect is a monoclonal antibody that blocks the activation of immune cells responsible for graft rejection. Its standard use in immunosuppressive protocols has considerably reduced rejection episodes since its approval in the past decade.

Given the growing demand and high price of these immunosuppressive drugs, cases of counterfeiting in the global market have increased, a phenomenon previously reported with other essential medicines.

Recommendations and continuous monitoring

International health authorities recommend that hospitals, clinics, and patients strengthen monitoring of the source and authenticity of medications used in kidney transplants.

It is essential that medical staff verify the origin of Simulect and that patients do not obtain these medications outside official and regulated channels. Additionally, WHO urges reporting any suspicion to avoid disruptions in immunosuppressive treatment.

Expert perspective and recent statistics

Experts note that medication counterfeiting in such delicate areas as transplants can increase postoperative mortality and morbidity. According to recent data, the acute kidney rejection rate can increase significantly when the quality of the immunosuppressant is not guaranteed.

In summary, the falsification of medication used in kidney transplants is an emerging threat that requires coordinated actions to protect this vulnerable population and preserve advances in transplant therapies.

WHO maintains active monitoring and will continue updating recommendations to protect the safety of patients who depend on Simulect.

Publicado en: https://orgullodominicano.org/en/falsification-of-medication-used-in-kidney-transplants-puts-patients-at-risk-in-several-countries/